170361-35-0 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
[4-(2,2,2-trifluoroethoxy)phenyl]acetic acid is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable component in the development of new drugs and agricultural chemicals, contributing to the advancement of these industries.
Used in Specialty Chemicals Production:
[4-(2,2,2-trifluoroethoxy)phenyl]acetic acid is also utilized in the production of various specialty chemicals, where its stability and solubility enhance the performance and functionality of the final products.
Used in Medicinal Chemistry and Drug Development:
Due to its pharmacological properties, [4-(2,2,2-trifluoroethoxy)phenyl]acetic acid has potential applications in the field of medicinal chemistry and drug development. Researchers and chemists can leverage its unique structure to design and synthesize new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 170361-35-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,3,6 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 170361-35:
(8*1)+(7*7)+(6*0)+(5*3)+(4*6)+(3*1)+(2*3)+(1*5)=110
110 % 10 = 0
So 170361-35-0 is a valid CAS Registry Number.
170361-35-0Relevant articles and documents
Novel benzimidazole derivatives as selective CB2 agonists
Pagé, Daniel,Balaux, Elise,Boisvert, Luc,Liu, Ziping,Milburn, Claire,Tremblay, Maxime,Wei, Zhongyong,Woo, Simon,Luo, Xuehong,Cheng, Yun-Xing,Yang, Hua,Srivastava, Sanjay,Zhou, Fei,Brown, William,Tomaszewski, Miroslaw,Walpole, Christopher,Hodzic, Leila,St-Onge, Stéphane,Godbout, Claude,Salois, Dominic,Payza, Keymal
scheme or table, p. 3695 - 3700 (2009/04/04)
The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.